Oxford’s COVID-19 Vaccine Makers To Parallel Clinical Studies
Merck KGaA, Halix NV, And Others Combine Expertise
Executive Summary
An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.